ATE258062T1 - Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren - Google Patents

Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren

Info

Publication number
ATE258062T1
ATE258062T1 AT99955974T AT99955974T ATE258062T1 AT E258062 T1 ATE258062 T1 AT E258062T1 AT 99955974 T AT99955974 T AT 99955974T AT 99955974 T AT99955974 T AT 99955974T AT E258062 T1 ATE258062 T1 AT E258062T1
Authority
AT
Austria
Prior art keywords
antagonists
tumors
treatment
growth hormone
hormone releasing
Prior art date
Application number
AT99955974T
Other languages
English (en)
Inventor
Giampiero Muccioli
Mauro Papotti
Ezio Ghigo
Romano Deghenghi
Original Assignee
Ardana Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardana Bioscience Ltd filed Critical Ardana Bioscience Ltd
Application granted granted Critical
Publication of ATE258062T1 publication Critical patent/ATE258062T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99955974T 1998-11-16 1999-11-11 Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren ATE258062T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/192,406 US6124263A (en) 1998-11-16 1998-11-16 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
PCT/EP1999/008662 WO2000029011A1 (en) 1998-11-16 1999-11-11 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists

Publications (1)

Publication Number Publication Date
ATE258062T1 true ATE258062T1 (de) 2004-02-15

Family

ID=22709509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955974T ATE258062T1 (de) 1998-11-16 1999-11-11 Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren

Country Status (30)

Country Link
US (1) US6124263A (de)
EP (1) EP1131083B1 (de)
JP (1) JP2002529512A (de)
KR (1) KR100704138B1 (de)
CN (3) CN1200726C (de)
AR (1) AR021286A1 (de)
AT (1) ATE258062T1 (de)
BG (1) BG105572A (de)
BR (1) BR9915390A (de)
CA (1) CA2350914A1 (de)
CO (1) CO5140111A1 (de)
CZ (1) CZ20011577A3 (de)
DE (1) DE69914365T2 (de)
DK (1) DK1131083T3 (de)
ES (1) ES2212650T3 (de)
HK (1) HK1040934A1 (de)
HU (1) HUP0104374A3 (de)
IL (1) IL142858A0 (de)
MX (1) MXPA01004689A (de)
NO (1) NO20012367L (de)
NZ (1) NZ511280A (de)
PL (1) PL347659A1 (de)
PT (1) PT1131083E (de)
RU (1) RU2240133C2 (de)
SK (1) SK6352001A3 (de)
TR (1) TR200101350T2 (de)
TW (2) TWI237565B (de)
UA (1) UA73100C2 (de)
WO (1) WO2000029011A1 (de)
ZA (1) ZA200103182B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
DE10112882A1 (de) * 2001-03-15 2002-09-19 Max Delbrueck Centrum Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren
US20040157227A1 (en) * 2001-05-10 2004-08-12 Chopin Lisa Kerstin Reproductive cancer diagnosis and therapy
EP1312363A1 (de) * 2001-09-28 2003-05-21 Pfizer Products Inc. Behandlungsverfahren und kits bestehend aus Wachstumshormonsekretionsförderern
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US20050164952A1 (en) * 2004-01-23 2005-07-28 Vital Pharmaceuticals, Inc. Delivery system for growth hormone releasing peptides
EP2021015A2 (de) * 2006-04-28 2009-02-11 The Administrators Of The Tulane Educational Fund Ghrelin/ghrp/ghsr-antagonisten und ihre verwendung
US8299022B2 (en) 2006-09-27 2012-10-30 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the N-terminal
CA2677813A1 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
WO2010118309A2 (en) * 2009-04-10 2010-10-14 Board Of Regents, The University Of Texas System Inhibitors of stat3 and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
IT1399610B1 (it) * 2010-01-28 2013-04-26 Univ Milano Bicocca Uso di agonisti e antagonisti dei recettori per i growth hormone secretagogues per la prevenzione e il trattamento di convulsioni ed epilessia
CA3129405A1 (en) 2019-02-08 2020-08-13 United States Government As Represented By The Department Of Veterans Affairs Growth hormone-releasing hormone antagonists and uses thereof
CN114126653B (zh) * 2019-07-18 2024-02-20 迈阿密大学 用于治疗结节病的方法的ghrh拮抗剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053250A1 (en) * 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
IT1240643B (it) * 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
GB2244063A (en) * 1990-05-15 1991-11-20 Exxon Research Engineering Co Grease composition containing inorganic compounds
RO117259B1 (ro) * 1993-08-09 2001-12-28 Biomeasure Inc. Derivaţi peptidici, terapeutici
US5550212A (en) * 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
US5807985A (en) * 1996-06-11 1998-09-15 Deghenghi; Romano Oligopeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone
US6063796A (en) * 1997-04-04 2000-05-16 Merck & Co., Inc. Somatostatin agonists

Also Published As

Publication number Publication date
WO2000029011A1 (en) 2000-05-25
DE69914365T2 (de) 2004-11-04
KR100704138B1 (ko) 2007-04-09
TR200101350T2 (tr) 2001-11-21
CN1895660A (zh) 2007-01-17
HK1040934A1 (zh) 2002-06-28
CA2350914A1 (en) 2000-05-25
HUP0104374A3 (en) 2003-03-28
UA73100C2 (en) 2005-06-15
TWI237565B (en) 2005-08-11
SK6352001A3 (en) 2002-09-10
AR021286A1 (es) 2002-07-03
TW200530270A (en) 2005-09-16
IL142858A0 (en) 2002-03-10
CZ20011577A3 (cs) 2002-07-17
JP2002529512A (ja) 2002-09-10
ZA200103182B (en) 2001-09-07
CN1277840C (zh) 2006-10-04
KR20010089459A (ko) 2001-10-06
ES2212650T3 (es) 2004-07-16
BR9915390A (pt) 2001-08-07
CN1200726C (zh) 2005-05-11
CO5140111A1 (es) 2002-03-22
PT1131083E (pt) 2004-06-30
BG105572A (en) 2002-01-31
TWI263642B (en) 2006-10-11
CN100368014C (zh) 2008-02-13
HUP0104374A2 (hu) 2002-04-29
PL347659A1 (en) 2002-04-22
DK1131083T3 (da) 2004-04-26
NO20012367D0 (no) 2001-05-14
RU2240133C2 (ru) 2004-11-20
DE69914365D1 (de) 2004-02-26
CN1326353A (zh) 2001-12-12
EP1131083A1 (de) 2001-09-12
US6124263A (en) 2000-09-26
MXPA01004689A (es) 2002-09-18
NZ511280A (en) 2002-10-25
NO20012367L (no) 2001-07-09
EP1131083B1 (de) 2004-01-21
CN1594358A (zh) 2005-03-16

Similar Documents

Publication Publication Date Title
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
EP1080113A4 (de) Behandlung von humanen tumoren mit bestrahlung und inhibitoren der wachstumsfaktorrezeptor-tyrosinkinase
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE255888T1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
ATE258062T1 (de) Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATE288300T1 (de) Erfassung von vorhofsignalen und mehrstelliger stimulation zur behandlung einer vorhofsfibrillierung
ATE300301T1 (de) Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
DE69940206D1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
DE122008000013I1 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131083

Country of ref document: EP

REN Ceased due to non-payment of the annual fee